Primary hormonal treatment for early endometrial carcinoma.
Four cases of clinical Stage I endometrial carcinoma initially treated with hormonal therapy are included in this study. Three of them resulted in tumor regression and two of them permitted a subsequent three pregnancies. All patients are alive and without evidence of disease with a median follow-up of 35.7 months (range 17 to 72 months). We believe this is a promising approach through which we may be able to offer a conservative treatment maintaining high survival rates and preserving childbearing potential. Diagnostic and therapeutic data for fertility-desiring patients with endometrial carcinoma are analyzed in this study.
Sardi
J
J
Gynecologic Oncology Unit, General Jose de San Martin Hospital, Buenos Aires University, Argentina.
Anchezar Henry
J P
JP
Paniceres
G
G
Gomez Rueda
N
N
Vighi
S
S
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001707:Biopsy, Needle; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000627:therapeutic use*; D009367:Neoplasm Staging; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D017258:Medroxyprogesterone Acetate